Basic | |
---|---|
Market Cap | $2.64M |
Price | $0.09 |
52 Week Range | 0.082-3.33 |
Beta | -0.04 |
Margins | |
Gross Profit Margin | 68.74% |
Operating Profit Margin | -149.90% |
Net Profit Margin | -82.85% |
Valuation (TTM) | |
P/E Ratio | -0.11 |
Price to Sales Ratio | 0.11 |
Price to Book Ratio | 0.45 |
PEG Ratio | -0.00 |
Biotechnology
Healthcare
90
2016-09-21T00:00:00.000Z
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
919 485 8080
4020 Stirrup Creek Drive, Durham, CA, 27703, US
0001467154